1. Home
  2. DNA vs DLY Comparison

DNA vs DLY Comparison

Compare DNA & DLY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • DNA
  • DLY
  • Stock Information
  • Founded
  • DNA 2008
  • DLY 2019
  • Country
  • DNA United States
  • DLY United States
  • Employees
  • DNA N/A
  • DLY N/A
  • Industry
  • DNA Biotechnology: Biological Products (No Diagnostic Substances)
  • DLY Investment Managers
  • Sector
  • DNA Health Care
  • DLY Finance
  • Exchange
  • DNA Nasdaq
  • DLY Nasdaq
  • Market Cap
  • DNA 658.5M
  • DLY 759.6M
  • IPO Year
  • DNA N/A
  • DLY N/A
  • Fundamental
  • Price
  • DNA $9.42
  • DLY $15.49
  • Analyst Decision
  • DNA Sell
  • DLY
  • Analyst Count
  • DNA 3
  • DLY 0
  • Target Price
  • DNA $9.67
  • DLY N/A
  • AVG Volume (30 Days)
  • DNA 1.6M
  • DLY 215.9K
  • Earning Date
  • DNA 08-07-2025
  • DLY 01-01-0001
  • Dividend Yield
  • DNA N/A
  • DLY 8.93%
  • EPS Growth
  • DNA N/A
  • DLY N/A
  • EPS
  • DNA N/A
  • DLY N/A
  • Revenue
  • DNA $237,417,000.00
  • DLY N/A
  • Revenue This Year
  • DNA N/A
  • DLY N/A
  • Revenue Next Year
  • DNA $15.91
  • DLY N/A
  • P/E Ratio
  • DNA N/A
  • DLY N/A
  • Revenue Growth
  • DNA 13.76
  • DLY N/A
  • 52 Week Low
  • DNA $5.00
  • DLY $13.26
  • 52 Week High
  • DNA $16.85
  • DLY $15.95
  • Technical
  • Relative Strength Index (RSI)
  • DNA 51.44
  • DLY 47.28
  • Support Level
  • DNA $9.75
  • DLY $15.33
  • Resistance Level
  • DNA $13.33
  • DLY $15.59
  • Average True Range (ATR)
  • DNA 0.87
  • DLY 0.10
  • MACD
  • DNA -0.18
  • DLY -0.01
  • Stochastic Oscillator
  • DNA 28.59
  • DLY 43.75

About DNA Ginkgo Bioworks Holdings Inc.

Ginkgo Bioworks Holdings Inc is the platform for cell programming, providing flexible, end-to-end services that solve challenges for organizations across diverse markets, from food and agriculture to pharmaceuticals to industrial and specialty chemicals. The Company reorganized its operations into two operating and reportable segments: Cell Engineering: where company provide biological R&D services for customers across a range of industries and Biosecurity: where it provide services to government and commercial customers to identify, monitor, prevent, mitigate, and ultimately protect humanity from biological threats. The maximum of revenue is from Cell Engineering Segment.

About DLY DoubleLine Yield Opportunities Fund of Beneficial Interest

DoubleLine Yield Opportunities Fund is a diversified, limited-term, closed-end management investment company. Its investment objective is to seek a high level of total return, with an emphasis on current income. The company invests in debt securities and other income-producing investments of issuers anywhere in the world, including in emerging markets, and may invest in investments of any credit quality. Its investment portfolio comprises foreign corporate bonds, foreign government bonds, non-agency commercial mortgage-backed obligations, U.S. corporate bonds, collateralized loan obligations, and bank loans among other securities.

Share on Social Networks: